Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total value of $82,365.00. Following the sale, the director now owns 9,500 shares in the company, valued at $521,645. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Alkermes PLC (NASDAQ:ALKS) traded down 0.04% during mid-day trading on Friday, hitting $50.90. The stock had a trading volume of 701,043 shares. The stock’s market cap is $7.82 billion. Alkermes PLC has a 12-month low of $41.93 and a 12-month high of $63.40. The firm’s 50-day moving average price is $55.78 and its 200 day moving average price is $57.15.
Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The firm had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. During the same period last year, the company earned ($0.01) EPS. The business’s quarterly revenue was up 12.1% compared to the same quarter last year. Equities analysts forecast that Alkermes PLC will post ($0.04) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of ALKS. Russell Investments Group Ltd. bought a new position in Alkermes PLC during the fourth quarter valued at about $439,000. Dimensional Fund Advisors LP raised its position in Alkermes PLC by 4.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 191,640 shares of the company’s stock valued at $10,651,000 after buying an additional 7,797 shares in the last quarter. Creative Planning raised its position in Alkermes PLC by 16.2% in the first quarter. Creative Planning now owns 18,012 shares of the company’s stock valued at $1,054,000 after buying an additional 2,510 shares in the last quarter. Capstone Asset Management Co. raised its position in Alkermes PLC by 8.0% in the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock valued at $385,000 after buying an additional 490 shares in the last quarter. Finally, Parametrica Management Ltd bought a new position in Alkermes PLC during the first quarter valued at about $518,000. Institutional investors and hedge funds own 97.19% of the company’s stock.
Several equities research analysts have issued reports on the company. J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Morgan Stanley reiterated an “equal weight” rating and issued a $62.00 price target on shares of Alkermes PLC in a report on Monday, April 24th. Leerink Swann downgraded Alkermes PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $68.00 to $61.00 in a report on Tuesday, June 13th. Finally, BidaskClub downgraded Alkermes PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Alkermes PLC has an average rating of “Hold” and a consensus price target of $63.00.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with our FREE daily email newsletter.